| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 8 | 2025 | 170 | 2.640 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2021 | 68 | 1.570 |
Why?
|
| Immunization, Passive | 9 | 2024 | 99 | 1.050 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2025 | 74 | 0.930 |
Why?
|
| Antibodies, Bispecific | 2 | 2023 | 29 | 0.930 |
Why?
|
| Dioxygenases | 1 | 2024 | 25 | 0.890 |
Why?
|
| Neoplastic Stem Cells | 4 | 2013 | 203 | 0.880 |
Why?
|
| Urticaria | 1 | 2023 | 7 | 0.870 |
Why?
|
| Mutation | 5 | 2025 | 2466 | 0.850 |
Why?
|
| Transfusion Reaction | 1 | 2023 | 46 | 0.850 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 23 | 0.730 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 42 | 0.720 |
Why?
|
| Stem Cell Transplantation | 2 | 2020 | 74 | 0.700 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2024 | 329 | 0.640 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 406 | 0.630 |
Why?
|
| Vaccination | 1 | 2021 | 342 | 0.610 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 1142 | 0.580 |
Why?
|
| Leukemia | 2 | 2016 | 54 | 0.530 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2016 | 12 | 0.520 |
Why?
|
| Antigens, CD34 | 3 | 2017 | 53 | 0.510 |
Why?
|
| Humans | 43 | 2025 | 60079 | 0.510 |
Why?
|
| Neoplasms | 3 | 2023 | 1262 | 0.480 |
Why?
|
| Phenotype | 2 | 2016 | 1145 | 0.470 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 646 | 0.470 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 62 | 0.450 |
Why?
|
| Stem Cells | 2 | 2013 | 258 | 0.440 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2013 | 275 | 0.440 |
Why?
|
| Transplantation Conditioning | 2 | 2024 | 94 | 0.380 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 405 | 0.360 |
Why?
|
| Disease Progression | 4 | 2024 | 1053 | 0.360 |
Why?
|
| Biomarkers | 1 | 2016 | 1214 | 0.360 |
Why?
|
| Outpatients | 4 | 2024 | 140 | 0.350 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2020 | 18 | 0.310 |
Why?
|
| Adult | 14 | 2025 | 15971 | 0.300 |
Why?
|
| Cytarabine | 2 | 2020 | 34 | 0.300 |
Why?
|
| Aged | 12 | 2025 | 13595 | 0.290 |
Why?
|
| Middle Aged | 12 | 2025 | 16541 | 0.270 |
Why?
|
| Male | 17 | 2025 | 27950 | 0.270 |
Why?
|
| Female | 18 | 2025 | 31225 | 0.260 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 302 | 0.240 |
Why?
|
| Prognosis | 4 | 2025 | 1591 | 0.230 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 28 | 0.230 |
Why?
|
| Staurosporine | 1 | 2024 | 19 | 0.220 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 83 | 0.220 |
Why?
|
| Graft vs Host Disease | 1 | 2024 | 103 | 0.220 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2025 | 168 | 0.220 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 171 | 0.200 |
Why?
|
| Cell Cycle Proteins | 1 | 2025 | 388 | 0.200 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 317 | 0.200 |
Why?
|
| Repressor Proteins | 1 | 2024 | 337 | 0.190 |
Why?
|
| Blast Crisis | 1 | 2021 | 10 | 0.190 |
Why?
|
| ADP-ribosyl Cyclase 1 | 2 | 2012 | 29 | 0.190 |
Why?
|
| Genes, p53 | 1 | 2021 | 53 | 0.190 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 80 | 0.180 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 5200 | 0.180 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 172 | 0.170 |
Why?
|
| Tretinoin | 3 | 2017 | 49 | 0.170 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 908 | 0.170 |
Why?
|
| Anthracyclines | 1 | 2020 | 10 | 0.170 |
Why?
|
| Mice, SCID | 2 | 2012 | 509 | 0.170 |
Why?
|
| Allografts | 1 | 2020 | 45 | 0.170 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2019 | 6 | 0.170 |
Why?
|
| Mice, Inbred NOD | 2 | 2012 | 516 | 0.170 |
Why?
|
| Voriconazole | 1 | 2019 | 6 | 0.170 |
Why?
|
| Invasive Fungal Infections | 1 | 2019 | 6 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 685 | 0.170 |
Why?
|
| Hospitalization | 2 | 2024 | 1304 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 300 | 0.160 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 95 | 0.160 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2018 | 11 | 0.160 |
Why?
|
| Antifungal Agents | 1 | 2019 | 116 | 0.160 |
Why?
|
| Tacrolimus | 1 | 2018 | 39 | 0.160 |
Why?
|
| Immunophenotyping | 2 | 2016 | 185 | 0.160 |
Why?
|
| Bone Marrow | 3 | 2016 | 177 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 225 | 0.150 |
Why?
|
| Hematologic Neoplasms | 2 | 2024 | 45 | 0.150 |
Why?
|
| United States | 5 | 2023 | 7622 | 0.150 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 191 | 0.150 |
Why?
|
| Telemedicine | 1 | 2023 | 337 | 0.150 |
Why?
|
| Myelopoiesis | 1 | 2017 | 14 | 0.140 |
Why?
|
| Double-Blind Method | 3 | 2024 | 684 | 0.140 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 304 | 0.140 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2016 | 1 | 0.140 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 1 | 2016 | 4 | 0.140 |
Why?
|
| Signal Transduction | 4 | 2017 | 2892 | 0.130 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 46 | 0.130 |
Why?
|
| Arabinonucleosides | 1 | 2016 | 2 | 0.130 |
Why?
|
| Adenine Nucleotides | 1 | 2016 | 4 | 0.130 |
Why?
|
| Mastocytosis | 1 | 2016 | 2 | 0.130 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2016 | 5 | 0.130 |
Why?
|
| Etoposide | 1 | 2016 | 35 | 0.130 |
Why?
|
| Karyotyping | 1 | 2016 | 43 | 0.130 |
Why?
|
| Dermatomycoses | 1 | 2016 | 13 | 0.130 |
Why?
|
| Leukopenia | 1 | 2016 | 16 | 0.130 |
Why?
|
| Niacinamide | 1 | 2016 | 32 | 0.130 |
Why?
|
| Phenylurea Compounds | 1 | 2016 | 30 | 0.130 |
Why?
|
| Cell Differentiation | 4 | 2017 | 1298 | 0.130 |
Why?
|
| Lymph Nodes | 2 | 2013 | 215 | 0.130 |
Why?
|
| Glycoproteins | 1 | 2017 | 192 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 152 | 0.120 |
Why?
|
| Mutation, Missense | 1 | 2016 | 178 | 0.120 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 324 | 0.120 |
Why?
|
| Young Adult | 4 | 2025 | 4398 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1471 | 0.120 |
Why?
|
| Bone Marrow Cells | 1 | 2016 | 232 | 0.120 |
Why?
|
| Down-Regulation | 2 | 2013 | 306 | 0.120 |
Why?
|
| Cell Proliferation | 3 | 2013 | 944 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 391 | 0.120 |
Why?
|
| Neutrophils | 1 | 2017 | 352 | 0.110 |
Why?
|
| Tissue Donors | 2 | 2024 | 134 | 0.110 |
Why?
|
| Automation, Laboratory | 1 | 2013 | 7 | 0.110 |
Why?
|
| Mice | 6 | 2013 | 10317 | 0.110 |
Why?
|
| Lymphoma, Follicular | 1 | 2013 | 15 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 34 | 0.110 |
Why?
|
| Splenic Rupture | 1 | 2013 | 2 | 0.110 |
Why?
|
| Sarcoma, Myeloid | 1 | 2013 | 4 | 0.110 |
Why?
|
| Cyclin D1 | 1 | 2013 | 21 | 0.110 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2013 | 14 | 0.110 |
Why?
|
| Recurrence | 2 | 2012 | 600 | 0.110 |
Why?
|
| Translocation, Genetic | 1 | 2013 | 63 | 0.110 |
Why?
|
| Chemokine CCL2 | 1 | 2013 | 54 | 0.110 |
Why?
|
| Transplantation, Autologous | 2 | 2024 | 120 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 453 | 0.100 |
Why?
|
| Treatment Outcome | 5 | 2024 | 5266 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2013 | 161 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2013 | 365 | 0.100 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 35 | 0.100 |
Why?
|
| Bone Marrow Transplantation | 1 | 2012 | 134 | 0.100 |
Why?
|
| Cells, Cultured | 2 | 2017 | 2095 | 0.100 |
Why?
|
| Cell Separation | 1 | 2012 | 146 | 0.090 |
Why?
|
| Cytosine | 1 | 2011 | 31 | 0.090 |
Why?
|
| DNA Repair | 1 | 2013 | 236 | 0.090 |
Why?
|
| WT1 Proteins | 1 | 2011 | 6 | 0.090 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 47 | 0.090 |
Why?
|
| Myeloblastin | 1 | 2011 | 14 | 0.090 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2011 | 13 | 0.090 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 38 | 0.090 |
Why?
|
| Telomerase | 1 | 2011 | 30 | 0.090 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 160 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 109 | 0.090 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 136 | 0.090 |
Why?
|
| Transcriptome | 1 | 2013 | 337 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2023 | 3132 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 713 | 0.080 |
Why?
|
| Cytokines | 2 | 2023 | 911 | 0.080 |
Why?
|
| Animals | 6 | 2013 | 19739 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 216 | 0.080 |
Why?
|
| Adolescent | 3 | 2024 | 5944 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 2009 | 56 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 329 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 853 | 0.080 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 1224 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 330 | 0.070 |
Why?
|
| Pandemics | 2 | 2023 | 628 | 0.070 |
Why?
|
| Cell Movement | 1 | 2009 | 426 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2009 | 552 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2011 | 1465 | 0.060 |
Why?
|
| Transplantation, Haploidentical | 1 | 2024 | 3 | 0.060 |
Why?
|
| HLA Antigens | 1 | 2024 | 59 | 0.060 |
Why?
|
| Blood Donors | 1 | 2024 | 21 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2024 | 236 | 0.060 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2024 | 26 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2025 | 262 | 0.050 |
Why?
|
| Interleukin-7 | 1 | 2023 | 30 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2023 | 83 | 0.050 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2023 | 7 | 0.050 |
Why?
|
| Safety-net Providers | 1 | 2023 | 34 | 0.050 |
Why?
|
| Syndrome | 1 | 2023 | 173 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 176 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1132 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 191 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 309 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 450 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 201 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 94 | 0.050 |
Why?
|
| Sweden | 1 | 2020 | 42 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2024 | 6147 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2022 | 306 | 0.040 |
Why?
|
| Universities | 1 | 2020 | 152 | 0.040 |
Why?
|
| Cost Savings | 1 | 2019 | 56 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2020 | 272 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 61 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 806 | 0.040 |
Why?
|
| Genotype | 1 | 2019 | 628 | 0.040 |
Why?
|
| HL-60 Cells | 1 | 2017 | 25 | 0.030 |
Why?
|
| Cytochromes c | 1 | 2017 | 26 | 0.030 |
Why?
|
| Neutrophil Activation | 1 | 2017 | 24 | 0.030 |
Why?
|
| Isoleucine | 1 | 2016 | 9 | 0.030 |
Why?
|
| Lactoferrin | 1 | 2017 | 37 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1111 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2017 | 53 | 0.030 |
Why?
|
| Exocytosis | 1 | 2017 | 59 | 0.030 |
Why?
|
| Threonine | 1 | 2016 | 14 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2017 | 59 | 0.030 |
Why?
|
| Glycosylation | 1 | 2017 | 133 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2017 | 195 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2016 | 5 | 0.030 |
Why?
|
| Arsenicals | 1 | 2016 | 7 | 0.030 |
Why?
|
| Oxides | 1 | 2016 | 33 | 0.030 |
Why?
|
| Pregnancy | 1 | 2023 | 2361 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 1481 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 250 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 638 | 0.030 |
Why?
|
| Retinoic Acid 4-Hydroxylase | 1 | 2013 | 3 | 0.030 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2013 | 4 | 0.030 |
Why?
|
| Retinal Dehydrogenase | 1 | 2013 | 6 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2013 | 24 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2013 | 26 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 76 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2013 | 10 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2013 | 10 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2013 | 58 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2013 | 22 | 0.030 |
Why?
|
| Luciferases | 1 | 2013 | 109 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2013 | 55 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2013 | 130 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2013 | 33 | 0.030 |
Why?
|
| DNA Primers | 1 | 2013 | 290 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 193 | 0.030 |
Why?
|
| Protein Binding | 1 | 2017 | 1571 | 0.020 |
Why?
|
| Spleen | 1 | 2013 | 486 | 0.020 |
Why?
|
| Biopsy | 1 | 2013 | 375 | 0.020 |
Why?
|
| 5-Methylcytosine | 1 | 2011 | 20 | 0.020 |
Why?
|
| Gestational Age | 1 | 2011 | 183 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2012 | 184 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2011 | 161 | 0.020 |
Why?
|
| Software | 1 | 2013 | 376 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2013 | 605 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 852 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 585 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 1565 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2009 | 76 | 0.020 |
Why?
|
| Child | 1 | 2016 | 4313 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 1387 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 3215 | 0.010 |
Why?
|